Lonza Completes Expansion of Conjugation Facility in Visp (CH)


  • The expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
  • Two manufacturing suites and supporting infrastructure are involved in the Visp (CH) investment


Article Summary

Lonza, announced that a planned expansion of its bioconjugation facility in Visp (CH) is completed. Two manufacturing suites and supporting infrastructure are included in the expansion. It will support an extended customer portfolio, including companies entering clinical development. The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates. 

Lonza’s recent investments and asset extensions in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity are complemented by the new suites. These continued investments into the Visp (CH) site provide a flexible solution for customers of all sizes at a single location. They are designed to help customers navigate the risks of a complex bioconjugation supply chain. The expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth, in addition to the two new manufacturing suites.

Stefan Egli, Vice President, Head of Bioconjugates, Lonza, commented: “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”


About Lonza 

Lonza is a global partner to the pharmaceutical, biotech and nutrition market with focus on enabling treatments that prevent illness and support healthier lifestyles. Lonza optimizes scientific innovation and manufacturing technology to enable customers to serve their patients and consumers. Lonza provides a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.


(Source: Lonza, 16th Feb 2023)


Leave A Comment

Leave a Reply

Your email address will not be published.